Galderma Receives China Approval for Relfydess
China’s NMPA approved Relfydess (relabotulinumtoxinA) to treat moderate-to-severe frown lines in adults.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.